Emerging treatments and evolving perspectives are shifting the management of chronic kidney disease from isolated control towards a comprehensive cardiovascular-metabolic approach, highlighting the importance of multidisciplinary care and recent pharmacological advances.
In a field long dominated by blood pressure control and glucose management, chronic kidney disease is being recast as part of a broader cardiovascular-kidney-metabolic syndrome, where the same patient may be living with diabetes, heart failure and declining kidney function at once. Tim Pflederer, chief medical officer for Evergreen Nephrology, said newer kidney-protective medicines have changed the outlook for many patients, but getting the right people on treatment still depends on more than a single clinic visit.
Pflederer argued that the key question is no longer whether a patient has diabetes, but whether they are at risk of progression. That shift matters because sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are now being used across related conditions, not just for glucose control. He also stressed that starting treatment well is essential: diabetes should be stabilised before an SGLT2 inhibitor is added, GLP-1 drugs should be introduced gradually, and patients need enough counselling to keep taking them.
That view is broadly consistent with kidney-focused guidance. The National Kidney Foundation says GLP-1 receptor agonists can help slow chronic kidney disease and reduce heart disease risk in adults with type 2 diabetes and/or obesity, and notes that current guidelines recommend a long-acting GLP-1 drug for adults with type 2 diabetes and CKD who have not yet reached diabetes goals with metformin and an SGLT2 inhibitor. The group also says the kidney-specific effects are not fully understood and that more research is needed, even as studies show reductions in albuminuria.
Recent evidence has strengthened the case for wider use, while also underlining the limits of what these medicines can do. A Cochrane review published in 2025 found GLP-1 receptor agonists probably reduce death from any cause and major cardiovascular events in people with CKD and diabetes, but probably have little or no effect on kidney failure or composite kidney outcomes. Separate systematic reviews and meta-analyses have reported lower risks of adverse renal outcomes, microalbuminuria and all-cause mortality, although gastrointestinal side effects remain a common drawback.
For Pflederer, that means implementation is now the main obstacle. He pointed to pharmacists as central to patient education and follow-through, and to the practical work of prior authorisation, monitoring and dose adjustment that often falls outside the narrow time available in routine appointments. In his view, the medicines are only part of the answer; the rest is building a care team that can identify eligible patients and help them stay on therapy.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
